title: Pharmacogenetics and coumarin dosing--recalibrating expectations.
authors: From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
authors: Issam
authors: I
authors: Zineh
authors: Michael
authors: M
authors: Pacanowski
authors: Janet
authors: J
authors: Woodcock
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage*; D000465:Algorithms; D000925:Anticoagulants / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D010644:Phenprocoumon / Q000008:administration & dosage*; D064417:Vitamin K Epoxide Reductases / Q000235:genetics*; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases; D000074:Acenocoumarol; D010644:Phenprocoumon